NCT07437963 2026-03-18
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Zhejiang Teruisi Pharmaceutical Inc.
Chinese PLA General Hospital
Chinese PLA General Hospital
SCG Cell Therapy Pte. Ltd.